https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21985 Wed 11 Apr 2018 15:20:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14469 Wed 11 Apr 2018 15:06:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14875 Wed 11 Apr 2018 11:51:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14536 500 ms was defined as abnormal. Results: Forty-six patients had Holter recordings after 10–40 mg droperidol and 316 QT–HR pairs were included. There were 32 abnormal QT measurements in four patients, three given 10 mg and one 20 mg. In three of the four patients QTcF >500 ms but only in one taking methadone was the timing of QTcF >500 ms consistent with droperidol dosing. Of the three other patients, one took amphetamines, one still had QT prolongation 24 h after droperidol and one took a lamotrigine overdose. No patient given >30 mg had a prolonged QT. There were no arrhythmias. Conclusion: QT prolongation was observed with high dose droperidol. However, there was little evidence supporting droperidol being the cause and QT prolongation was more likely due to pre-existing conditions or other drugs.]]> Wed 11 Apr 2018 11:05:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14404 Wed 11 Apr 2018 10:15:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14539 65 years) with ABD requiring parenteral sedation and physical restraint in the ED. Patients were treated with a standardized sedation protocol that included droperidol. Drug administration, time to sedation, additional sedation, and adverse effects were recorded. Effective sedation was defined as a drop in the sedation assessment tool score by 2 or a score of zero or less. Main Findings: There were 49 patients with median age of 81 years (range, 65-93 years); 33 were males. Thirty patients were given 10 mg droperidol, 15 were given 5 mg droperidol, 2 were given 2.5 mg, and 2 were given midazolam. Median time to sedation for patients receiving 10 mg droperidol was 30 minutes (interquartile range, 18-40 minutes), compared with 21 minutes (interquartile range, 10-55 minutes; P = .55) for patients receiving 5 mg droperidol. Three patients were not sedated within 120 minutes. Eighteen patients required additional sedation—10 of 30 (33%; 95% confidence interval, 18%-53%) given droperidol 10 mg compared with 7 of 15 (47%; 95% confidence interval, 22%-73%) given 5 mg. Fourteen patients required resedation. Adverse effects occurred in 5 patients (hypotension [2], oversedation [2], hypotension/oversedation [1])—2 of 30 given 10 mg droperidol and 3 of 19 not treated according to protocol. Midazolam was given initially or for additional sedation in 2 of 5 adverse effects. No patient had QT prolongation. Principal Conclusions: Droperidol was effective for sedation in most elderly patients with ABD, and adverse effects were uncommon. An initial 5-mg dose appears prudent with the expectation that many will require another dose.]]> Tue 31 Jul 2018 16:07:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33894 Tue 03 Sep 2019 18:02:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7545 Sat 24 Mar 2018 10:46:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11519 Sat 24 Mar 2018 08:10:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20692 Sat 24 Mar 2018 07:55:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28152 Sat 24 Mar 2018 07:36:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29671 –1 provided a stable model and lowest objective function. This represents extremely rapid absorption with a half-life of 5 min. The final model had a clearance of 41.9 l h^–1 and volume of distribution of the central compartment of, 73.6 l. Median and interquartile range of initial (alpha) half-life was 0.32 h (0.26–0.37 h) and second (beta) half-life was 3.0 h (2.5–3.6 h). Simulations indicate that 10 mg alone provides an 80% probability of being above the lower limit of quantification (5 μg l^–1) for 7 h, 2 h longer than for 5 mg. Giving two 10 mg doses increased this duration to 10 h. Conclusions: Intramuscular droperidol is rapidly absorbed with high therapeutic concentrations after 5 and 10 mg doses, and supports clinical data in which droperidol sedates rapidly for up to 6 h.]]> Sat 24 Mar 2018 07:32:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26936 Sat 24 Mar 2018 07:27:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49253 Mon 08 May 2023 10:55:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46134 Fri 11 Nov 2022 15:28:49 AEDT ]]>